Home » Stocks » AFMD

Affimed N.V. (AFMD)

Stock Price: $8.15 USD -0.05 (-0.61%)
Updated Jun 11, 2021 4:00 PM EDT - Market closed
After-hours: $8.16 +0.01 (0.12%) Jun 11, 5:48 PM
Market Cap 965.30M
Revenue (ttm) 34.59M
Net Income (ttm) -50.45M
Shares Out 118.95M
EPS (ttm) -0.60
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day June 11
Last Price $8.15
Previous Close $8.20
Change ($) -0.05
Change (%) -0.61%
Day's Open 8.20
Day's Range 8.03 - 8.34
Day's Volume 547,656
52-Week Range 2.90 - 11.74

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Heidelberg, Germany, May 26, 2021 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that its...

2 weeks ago - GlobeNewsWire

Heidelberg, Germany, May 20, 2021 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that its...

3 weeks ago - GlobeNewsWire

Affimed NV (NASDAQ: AFMD) has announced the publication of in vitro and in vivo research of its lead innate cell engager (ICE), AFM13 (CD16A/CD30), combined with healthy donor-derived Natural killer (NK...

4 weeks ago - Benzinga

This biotech stock has already produced some big returns this year.

4 weeks ago - The Motley Fool

AFM13 in combination with natural killer (NK) cells demonstrated improved tumor recognition and enhanced tumor cell killing in vitro and in vivo.

4 weeks ago - GlobeNewsWire

Affimed (AFMD) has moved higher as of late, but there could definitely be trouble on the horizon for this company

1 month ago - Zacks Investment Research

The company's latest quarterly update was less than impressive.

1 month ago - The Motley Fool

Heidelberg, Germany, April 15, 2021 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today reported financi...

1 month ago - GlobeNewsWire

Heidelberg, Germany, April 12, 2021 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announces pre-clinical...

2 months ago - GlobeNewsWire

A 100% response rate is impressive, albeit in just four patients.

2 months ago - The Motley Fool

Affimed NV (NASDAQ: AFMD) has announced initial clinical data from an investigator-sponsored study evaluating cord blood-derived natural killer (cbNK) cells pre-complexed with Affimed's innate cell enga...

2 months ago - Benzinga

Heidelberg, Germany, April 8, 2021 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it...

2 months ago - GlobeNewsWire

While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

Other stocks mentioned: CMRX, EPZM, SEEL, WVE
2 months ago - 24/7 Wall Street

Heidelberg, Germany and Santa Ana, Calif., March 31, 2021 - Affimed N.V. (NASDAQ: AFMD), a clinical-stage immuno-oncology company, and NKMax America Inc., a clinical stage biotech company, announced tod...

2 months ago - GlobeNewsWire

Heidelberg, Germany, March 10, 2021 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that p...

3 months ago - GlobeNewsWire

Following the Independent Review Committee's assessment, Affimed NV (NASDAQ: AFMD) will continue enrollment in Phase 2 REDIRECT trial evaluating AFM13 as a monotherapy for relapsed or refractory CD30-po...

3 months ago - Benzinga

Heidelberg, Germany, March 10, 2021 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today its de...

3 months ago - GlobeNewsWire

Steven Cohen (Trades, Portfolio), the billionaire investor who leads Point72 Asset Management, disclosed earlier this week his firm upped its stake in Affimed NV (NASDAQ:AFMD) by 190.73%.

4 months ago - GuruFocus

Affimed N.V. (NASDAQ: AFMD) has entered into a clinical research collaboration with Roche Holding AG (OTC: RHHBF) to explore the combination of Affimed's AFM24 with Roche's atezolizumab (Tecentriq) for ...

Other stocks mentioned: RHHBY
4 months ago - Benzinga

Heidelberg, Germany, February 3, 2021 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that...

4 months ago - GlobeNewsWire

Heidelberg, Germany, January 15, 2021 – Affimed N.V. (“Affimed” or the “Company”) (Nasdaq: AFMD), a clinical stage immuno-oncology company committed to giving patients back their innate ability to fight...

4 months ago - GlobeNewsWire

Affimed (AFMD) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

4 months ago - Zacks Investment Research

Heidelberg, Germany, January 13, 2021 – Affimed N.V. (“Affimed” or the “Company”) (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight...

4 months ago - GlobeNewsWire

Heidelberg, Germany, January 12, 2021 – Affimed N.V. (“Affimed” or the “Company”) (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight...

5 months ago - GlobeNewsWire

Heidelberg, Germany, January 11, 2021 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that...

5 months ago - GlobeNewsWire

Heidelberg, Germany, January 11, 2021 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that...

5 months ago - GlobeNewsWire

Heidelberg, Germany, January 7, 2021 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced an up...

5 months ago - GlobeNewsWire

Affimed continues to amass a stockpile of partnerships and collaborations that amplifies the risk-reward profile for an AFMD investment. As a result, I am looking to accumulate a larger position. I prov...

5 months ago - Seeking Alpha

Heidelberg, Germany, December 7, 2020 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced the ...

6 months ago - GlobeNewsWire

 The phase 1b study showed a complete response (CR) rate of 46% (objective response rate [ORR] of 88%) at the recommended dose level in patients with relapsed/refractory (R/R) Hodgkin lymphoma, whereas ...

6 months ago - GlobeNewsWire

Affimed N.V. (AFMD) CEO Adi Hoess on Q3 2020 Results - Earnings Call Transcript

7 months ago - Seeking Alpha

Affimed N.V.'s (AFMD) CEO Adi Hoess On Q3 2020 Results - Quick Version Earnings Call Transcript

7 months ago - Seeking Alpha

Affimed N.V. (AFMD) delivered earnings and revenue surprises of 33.33% and 94.55%, respectively, for the quarter ended September 2020.

7 months ago - Zacks Investment Research

Shares of Affimed (NASDAQ:AFMD) rose 11.3% in pre-market trading after the company reported Q3 results. Quarterly Results Earnings per share increased 57.89% over the past year to ($0.08), which beat th...

7 months ago - Benzinga

Heidelberg, Germany, Novembe r 10 , 2020 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today reported fi...

7 months ago - GlobeNewsWire

Affimed to grant license to AFM32 with options for additional ICE® molecules directed against targets not included in Affimed's current pipeline

7 months ago - GlobeNewsWire

 Virtual data presentation at The Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting on Wednesday, November 11, 2020

7 months ago - GlobeNewsWire

 Exclusive collaboration to assess feasibility and activity of pre-manufactured, co-vialed, cryopreserved, off-the-shelf NK cell combination therapeutics targeting EGFR and additional targets

7 months ago - GlobeNewsWire

Heidelberg, Germany, November 4, 2020 – Affimed N.V., (NASDAQ: AFMD) a clinical stage biopharmaceutical company committed to giving patients back their innate ability to fight cancer, announced today th...

7 months ago - GlobeNewsWire

Heidelberg, Germany, November 4, 2020 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that...

7 months ago - GlobeNewsWire

Heidelberg, Germany, November 3, 2020 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that...

7 months ago - GlobeNewsWire

Heidelberg, Germany, and Santa Ana, California, October 20, 2020 – Affimed N.V. (NASDAQ: AFMD) and NKMax America Inc., both clinical stage biotech companies focused on harnessing the power of the body's...

7 months ago - GlobeNewsWire

Heidelberg, Germany, October 14, 2020 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that...

7 months ago - GlobeNewsWire

Pilsen, Czech Republic, October 6, 2020 - AbCheck s.r.o., a leader in providing antibody drug discovery, engineering and optimization services to the biotech and pharmaceutical industry, today announced...

8 months ago - GlobeNewsWire

Heidelberg, Germany, October 6, 2020 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that ...

8 months ago - GlobeNewsWire

Heidelberg, Germany, September 29, 2020 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced th...

8 months ago - GlobeNewsWire

 Heidelberg, Germany, September 2, 2020 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced th...

9 months ago - GlobeNewsWire

Affimed N.V. (AFMD) CEO Adi Hoess on Q2 2020 Results - Earnings Call Transcript

10 months ago - Seeking Alpha

Affimed N.V. (AFMD) delivered earnings and revenue surprises of -50.00% and -52.45%, respectively, for the quarter ended June 2020.

10 months ago - Zacks Investment Research

About AFMD

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Europe, and Germany. Its lead product candidate is AFM13, which has completed Phase II clinical study of CD30-positive T-cell lymphoma, and hodgkin lymphoma (HL), as well as is in Phase II clinical trials for peripheral T-cell lymphoma, and transformed mycosis fungoides; that is in Phase I clinical study in combination with adoptive NK cells for CD30-postive lymphomas; and has completed Phase Ib clinical s... [Read more...]

Industry
Biotechnology
IPO Date
Sep 12, 2014
Stock Exchange
NASDAQ
Ticker Symbol
AFMD
Full Company Profile

Financial Performance

In 2020, Affimed N.V.'s revenue was 28.36 million, an increase of 32.58% compared to the previous year's 21.39 million. Losses were -41.37 million, 27.8% more than in 2019.

Financial numbers in millions EUR.
Financial Statements

Analyst Forecasts

According to 5 analysts, the average rating for Affimed N.V. stock is "Strong Buy." The 12-month stock price forecast is 15.41, which is an increase of 89.08% from the latest price.

Price Target
$15.41
(89.08% upside)
Analyst Consensus: Strong Buy